Clinical trial
The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Very Elderly: the TAHOC Study
Name
2023PI017
Description
Neurocognitive disorders and hypertension occur commonly with aging. While, by definition, older adults are at high cardiovascular risk, there is no guideline exist currently on blood pressure management of elderly hypertension. However, studies have shown that in aging adults, high blood pressure helps prevent against cognitive decline, and low blood pressure on antihypertensive drugs could accelerate it. This study aims at investigating if pharmacological treatment of hypertension in the very elderly is influenced by presence and severity of neurocognitive disorders. Our research hypothesis is that the drug management of hypertension in patients 80 years of age or older more is all the less aggressive as the neurocognitive disorders are advanced.
Trial arms
Trial start
2022-01-01
Estimated PCD
2022-01-01
Trial end
2022-12-12
Status
Completed
Treatment
Antihypertensive Agents
number of hypertensive drugs
Arms:
control group, mild neurocognitive disorder, moderate neurocognitive disorder, severe neurocognitive disorder
Size
353
Primary endpoint
number of antihypertensive agents
during inclusion
Eligibility criteria
Inclusion Criteria:
* to be 80 years of age
* with history of hypertension and/or on hypertensive drug(s)
Exclusion Criteria:
* legal protection measure.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 353, 'type': 'ACTUAL'}}
Updated at
2023-05-06
1 organization
1 product
5 indications
Organization
Central HospitalProduct
Antihypertensive AgentsIndication
Neurocognitive DisordersIndication
DementiaIndication
HypertensionIndication
ElderlyIndication
80 and Over